|
Composition |
Each capsule contains particles dissolve in the intestine contains lansoprazole 30 mg |
|
Pharmacodynamic /pharmacologicalproperties |
Lansoprazole is an inhibitor of proton pump blockers final step in the process of more gastric acid by forming a link to assimilate to the second side of the enzyme (H +, K +)-ATPase at the cell surface information into the stomach. This effect is dose-related and leads to inhibition of both gastric acid secretion: basic and due to irritation regardless of the form of irritation. Enamel bond (H +, K +)-ATPase results in anti excretion lasted more than 24 hours. |
|
Ppecify |
Absorption of lansoprazole fast and reached a concentration of about 1.5 hours. Lansoprazole with food can reduce the bioavailability of the drug, however, does not alter the effects of drugs on the inhibition of gastric acid secretion. The plasma protein binding of lansoprazole around 97%. The plasma half-life of lansoprazole is about 1.4 hours and did not change during treatment. Completely eliminated after major changes in the liver. The metabolites are not active and toxic and is excreted mainly in the bile. Pharmacological effects no change in the elderly. |
|
Contraindications |
Lansolek is indicated for the treatment of:
- Peptic ulcer
- Duodenal ulcer progression
- Inflammation of the esophagus at the moderate and severe reflux
- Coordinate antibiotics kill bacteria H. pylori |
|
Dosage /use |
Hypersensitivity toanycomponent ofthedrug |
|
Do not want to effect/side effects |
The recommended dose for adults orally is 1 tablet / day. Treatment time from 4-8 weeks depending on the condition and recommended by the physician. Capsules containing particles dissolve in the intestine should be taken with water and swallowed whole, do not chew or break. |
|
Packing |
Common symptoms such as: headache, diarrhea, nausea, abdominal pain, flatulence .... usually transient and do not stop taking the medication.
DRUG INTERACTIONS: So far have not seen any significant drug interactions have been reported. |
|
Preservation |
Not recommended for pregnant women and breast-feeding or considering the benefits of the drug and the risk for pregnancy and infant during this time. Safety and effectiveness in pediatric patients have not been studied need to adjust the dose in patients with hepatic impairment. |
|
Marketing anddistribution |
Box of10blistersx10tablets |
|
Ppecify |
A cool dry place, protected from light, out of reach of children |
|
Contraindications |
INFO PHARMA |
